Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.34 |
| ▸ | HTR1A | P08908 | 4/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 6/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23594104 | 0.82 | HTR7 (0.36) | SIGMAR1HTR1AHTR7NPC1PDCD1 | |
| SCHEMBL24926155 | 0.82 | HTR7 (0.38) | SIGMAR1HTR1AHTR7NPC1PDCD1 | |
| SCHEMBL26827171 | 0.80 | HTR1A (0.35) | SIGMAR1HTR1AHTR7NPC1PDCD1 | |
| SCHEMBL24926663 | 0.80 | PDCD1 (0.41) | SIGMAR1HTR1AHTR7NPC1PDCD1 | |
| SCHEMBL26827161 | 0.80 | HTR7 (0.36) | SIGMAR1HTR1AHTR7NPC1PDCD1 | |
| SCHEMBL24926264 | 0.78 | HTR7 (0.35) | SIGMAR1HTR1AHTR7NPC1PDCD1 | |
| SCHEMBL26804172 | 0.78 | HTR1A (0.35) | SIGMAR1HTR1AHTR7NPC1PDCD1 | |
| SCHEMBL26810946 | 0.70 | HSD11B1 (0.43) | SIGMAR1HTR1AHTR7NPC1PDCD1 | |
| SCHEMBL16219507 | 0.69 | MAPK1 (0.58) | DRD2DRD4MEN1KMT2A | |
| SCHEMBL16219392 | 0.69 | PAOX (0.58) | SIGMAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | SIGMAR1 4492/4885HTR1A 4414/4885HTR7 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.